MeSH D011704 - pyelonephritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ciprofloxacin | Ciprofloxacin |  | 2004-06-09 |  |  |
| Levofloxacin | Levofloxacin |  | 2011-06-20 |  |  | |
| Taro Pharmaceutical | Ciprofloxacin | Ciprofloxacin |  | 2004-10-06 |  |  |
| Glenmark Pharmaceuticals | Levofloxacin | Levofloxacin |  | 2011-06-20 |  |  |
| Mylan | Ciprofloxacin | Ciprofloxacin |  | 2004-06-09 |  |  |
| Levofloxacin | Levofloxacin |  | 2011-06-20 |  |  | |
| Johnson & Johnson | Levofloxacin | Levaquin |  | 1996-12-20 |  |  |
| Cipla | Plazomicin | Zemdri | 2028-11-21 | 2018-06-25 |  |  |
| Lupin Research | Levofloxacin | Levofloxacin |  | 2011-06-20 |  |  |
| Sandoz | Levofloxacin | Levofloxacin |  | 2011-06-20 |  |  |
| Ciprofloxacin | Ciloxan |  | 1990-12-31 |  |  | |
| Hydrocortisone, Ciprofloxacin | Cipro |  | 1998-02-10 |  |  | |
| Dexamethasone, Ciprofloxacin | Ciprodex | 2025-06-04 | 2003-07-18 |  |  | |
| Merck Sharp & Dohme | Ertapenem | Invanz |  | 2001-11-21 | $189 M | Y2022 |
| Cilastatin, Imipenem, Relebactam | Recarbrio | 2029-11-19 | 2019-07-16 |  |  |
1
2
3
4
5
6
...
8
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/1
Phase 2
59%10/17
Phase 3
56%19/34
Approved: 9Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use